BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 32494016)

  • 1. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
    Słabicki M; Kozicka Z; Petzold G; Li YD; Manojkumar M; Bunker RD; Donovan KA; Sievers QL; Koeppel J; Suchyta D; Sperling AS; Fink EC; Gasser JA; Wang LR; Corsello SM; Sellar RS; Jan M; Gillingham D; Scholl C; Fröhling S; Golub TR; Fischer ES; Thomä NH; Ebert BL
    Nature; 2020 Sep; 585(7824):293-297. PubMed ID: 32494016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.
    Lv L; Chen P; Cao L; Li Y; Zeng Z; Cui Y; Wu Q; Li J; Wang JH; Dong MQ; Qi X; Han T
    Elife; 2020 Aug; 9():. PubMed ID: 32804079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational discovery of molecular glue degraders via scalable chemical profiling.
    Mayor-Ruiz C; Bauer S; Brand M; Kozicka Z; Siklos M; Imrichova H; Kaltheuner IH; Hahn E; Seiler K; Koren A; Petzold G; Fellner M; Bock C; Müller AC; Zuber J; Geyer M; Thomä NH; Kubicek S; Winter GE
    Nat Chem Biol; 2020 Nov; 16(11):1199-1207. PubMed ID: 32747809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design principles for cyclin K molecular glue degraders.
    Kozicka Z; Suchyta DJ; Focht V; Kempf G; Petzold G; Jentzsch M; Zou C; Di Genua C; Donovan KA; Coomar S; Cigler M; Mayor-Ruiz C; Schmid-Burgk JL; Häussinger D; Winter GE; Fischer ES; Słabicki M; Gillingham D; Ebert BL; Thomä NH
    Nat Chem Biol; 2024 Jan; 20(1):93-102. PubMed ID: 37679459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
    Dieter SM; Siegl C; Codó PL; Huerta M; Ostermann-Parucha AL; Schulz E; Zowada MK; Martin S; Laaber K; Nowrouzi A; Blatter M; Kreth S; Westermann F; Benner A; Uhrig U; Putzker K; Lewis J; Haegebarth A; Mumberg D; Holton SJ; Weiske J; Toepper LM; Scheib U; Siemeister G; Ball CR; Kuster B; Stoehr G; Hahne H; Johannes S; Lange M; Herbst F; Glimm H
    Cell Rep; 2021 Jul; 36(3):109394. PubMed ID: 34289372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule degraders of cyclin-dependent kinase protein: a review.
    Yu B; Du Z; Zhang Y; Li Z; Bian J
    Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors.
    Thomas KL; Bouguenina H; Miller DSJ; Sialana FJ; Hayhow TG; Choudhary JS; Rossanese OW; Bellenie BR
    ACS Chem Biol; 2024 Jan; 19(1):173-184. PubMed ID: 38193430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
    Kozicka Z; Thomä NH
    Cell Chem Biol; 2021 Jul; 28(7):1032-1047. PubMed ID: 33930325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma.
    Houles T; Boucher J; Lavoie G; MacLeod G; Lin S; Angers S; Roux PP
    Cell Death Discov; 2023 Dec; 9(1):459. PubMed ID: 38104154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
    Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
    Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of Cyclin-Dependent Kinases Triggers Anti-Fibrotic Effects in Hepatic Stellate Cells In Vitro.
    Hübbers A; Hennings J; Lambertz D; Haas U; Trautwein C; Nevzorova YA; Sonntag R; Liedtke C
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.
    Montagnoli A; Fiore F; Eytan E; Carrano AC; Draetta GF; Hershko A; Pagano M
    Genes Dev; 1999 May; 13(9):1181-9. PubMed ID: 10323868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of small molecule degraders for modulating cell cycle.
    Wang L; Yang Z; Li G; Liu Y; Ai C; Rao Y
    Front Med; 2023 Oct; 17(5):823-854. PubMed ID: 37935945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New functional activities for the p21 family of CDK inhibitors.
    LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
    Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
    Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
    J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.